Mangoceuticals Gross Profit

The latest gross profit for MGRX is $170K as of June 2026. That compares with $310K in the prior-year period — down 45.5% year over year. That is below the sector sector average of $750M. Investors often review this figure alongside Mangoceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, MGRX's gross profit moved from $310K to $170K — a 45.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mangoceuticals's operating scale or balance-sheet position.

Against its sector companies, MGRX currently prints $170K for gross profit, while the sector average sits near $750M. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Mangoceuticals's growth, margins, and balance sheet.

A gross profit figure of $170K for MGRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $750M. Explore the charts below for those layers of context.

After noting MGRX's gross profit ($170K), review year-over-year change from $310K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.